Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

Novel 5-lipoxygenase inhibitors described by Pfizer

July 12, 1996

Naphthoquinone derivative selected as potential antiallergic/antiinflammatory

July 5, 1996

Uriach research into PAF antagonists continues

July 5, 1996

New beclomethasone formulation cleared for marketing

July 5, 1996

Trials terminated for HyperGAM+ for Pseudomonas lung infections

June 28, 1996

FK-506 undergoes phase II trials

June 28, 1996

Adenosine A3 antagonists from Merck & Co.

June 28, 1996

Eisai's ER-27319: Potential in treating allergic diseases

June 28, 1996

GCC-AP0341: Green Cross' eosinophilia inhibitor

June 28, 1996

5-lipoxygenase and cyclooxygenase inhibitors from Abbott

June 28, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 12, 2025.
Deep Apple signs big Novo deal for cardiometabolic small molecules
BioWorld
Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
23andme genetic privacy concerns garner Congressional scrutiny
BioWorld MedTech
The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...
3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race
BioWorld
3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...